Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Orally Bioavailable Androgen Receptor Degrader, Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Nov 2019

Ponnusamy Suriyan, He Yali, Hwang Dong-Jin, Thiyagarajan Thirumagal, Houtman Rene, Bocharova Vera, Sumpter Bobby G, Fernandez Elias, Johnson Daniel, Du Ziyun, Pfeffer Lawrence M, Getzenberg Robert H, McEwan Iain J, Miller Duane D, Narayanan Ramesh

Abstract excerpt

PURPOSE: Androgen receptor (AR)-targeting prostate cancer drugs, which are predominantly competitive ligand-binding domain (LBD)-binding antagonists, are inactivated by common resistance mechanisms. It is important to develop next-generation mechanistically distinct drugs to treat castration- and drug-resistant prostate cancers. EXPERIMENTAL DESIGN: Second-generation AR pan antagonist UT-34 was selected from a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Androgen Receptor Antagonists

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Benzamides

Share to Nitriles

Share to Proteasome Endopeptidase Complex

Share to Proteolysis

Share to Receptors, Androgen

Share to Ubiquitin

Source

Identifiers

PMID: 31481513
DOI: 10.1158/1078-0432.CCR-19-1458

Genes

AR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Orally Bioavailable Androgen Receptor Degrader, Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate Cancer.PMID 31481513Read ↗

Androgen receptor antagonists: a patent review (2008-2011).Semantic proximity Read ↗

Bypassing Drug Resistance Mechanisms of Prostate Cancer with Small Molecules that Target Androgen Receptor–Chromatin InteractionsSemantic proximity Read ↗

In Silico Discovery of Androgen Receptor Antagonists with Activity in Castration Resistant Prostate CancerSemantic proximity Read ↗

Molecular pathways: targeting resistance in the androgen receptor for therapeutic benefit.Semantic proximity Read ↗

A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509Semantic proximity Read ↗

Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatmentSemantic proximity Read ↗

Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor.Semantic proximity Read ↗

Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).Semantic proximity Read ↗

Selective androgen receptor degrader (SARD) to overcome antiandrogen resistance in castration-resistant prostate cancerSemantic proximity Read ↗

Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC).Semantic proximity Read ↗

Selectively targeting the dimerization interface of human androgen receptor with small-molecules to treat castration-resistant prostate cancer.Semantic proximity Read ↗

Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.